Novavax rises 20.1% after reports Sanofi will carry Nuvaxovid into fall season

What happened

Novavax (NVAX) rose 20.1% on October 5, 2026, after reports that Sanofi will carry the Nuvaxovid COVID-19 vaccine into the fall vaccination season, according to Benzinga and Zacks Investment Research. The stock was reported at $12 during the intraday move and closed at $12.56. Trading volume ran 5.5 times its 20-day average, and market commentators noted heavy short interest during the rally.

How big was the move

The stock rose 20.1% in a session that was 5.1 times a typical daily move for this stock, a pattern the data characterize as a large, mostly company-specific move because Novavax moved far more than the market and its sector. The S&P 500 on the day rose 0.7% and the Healthcare sector median on the day rose 0.8%, leaving the stock 19.3 percentage points better than the sector median. Over the last five sessions the stock rose 16.3%, while the S&P 500 over five sessions rose 1.2%.

The technical picture

The stock traded 21.9% above its 20-day moving average, 36.6% above its 50-day moving average and 40.9% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 31 consecutive trading days above the 200-day average. The Relative Strength Index (14 days) is 77, above 70, a level often called overbought, which suggests momentum may be extended. The stock is 6.2% below the 52-week high. Over one month the stock rose 21.5% and over three months it rose 32.8%, while over one year it rose 31.5%, 15.8 percentage points ahead of the S&P 500. Volatility was 62% annualized over 60 days, lower than 88% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $413.8 million, a decline of 61.6% from a year earlier and a decline of 52.5% from one quarter earlier. Diluted earnings per share were $-1.52, with earnings per share growth from a year earlier that fell 167.3%. Gross margin stood at 77.9%, down from 88.4% a year earlier, while operating margin was 54.9% versus 33.0% a year earlier. Free-cash-flow margin was 10.5% and return on invested capital was 36.1%. Share count over one year decreased by 7.1%. Valuation shows a free-cash-flow yield of 2.5%.

Those figures show sharply lower revenue alongside durable margin metrics and positive cash conversion. The contrast — weak top-line trends against healthy margins and a falling share count — underpins the mixed view investors had coming into the session and helps explain why a positive commercial development produced an outsized stock reaction.

Earnings and analyst expectations

Novavax last reported on August 6, 2026, with earnings per share of $-0.32 against $-0.38 expected, 15.8% above estimates. That marked three consecutive quarters beating estimates and an average surprise over the last four reports of 48.2% above estimates. The typical two-day reaction after recent reports was that the stock rose 5.9%. The next report is scheduled for November 5, 2026.

Analyst coverage includes 23 firms and the consensus rating is Buy. Seventy-four percent of analyst ratings fell into the Buy-related category, and the consensus price target is $18.00, 43.3% above the closing price.

What to watch

• November 5, 2026: Novavax next earnings report date.
• Consensus price target: $18.00, 43.3% above the closing price.
• Trading volume on October 5, 2026: 5.5 times its 20-day average and the intraday report noted the stock at $12.
• Similar sessions in the past five years: eight sessions with a gain of at least 20.1%; twenty trading days later the median result was a decline of 13.1%, and 2 of 8 were higher.
• Market sensitivity: beta of 1.58; the stock tends to move more than the market.